To evaluate the combination of lenvatinib and pembrolizumab in patients with advanced melanoma with confirmed progression on a PD-1/L1 inhibitor, the LEAP-004 study (NCT03776136) was performed. This evidence concerns the gene PDCD1 and melanoma.